Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 88.62 kCr |
| Price/Earnings (Trailing) | 50.41 |
| Price/Sales (Trailing) | 6.33 |
| EV/EBITDA | 25.76 |
| Price/Free Cashflow | 51.99 |
| MarketCap/EBT | 41.17 |
| Enterprise Value | 96.66 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | -4.3% |
| Price Change 1M | -3.7% |
| Price Change 6M | -17.5% |
| Price Change 1Y | -14.7% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -12.68 kCr |
| Cash Flow from Operations (TTM) | 2.41 kCr |
| Revenue (TTM) |
| 14 kCr |
| Rev. Growth (Yr) | 18.9% |
| Earnings (TTM) | 1.77 kCr |
| Earnings Growth (Yr) | -21.1% |
Profitability | |
|---|---|
| Operating Margin | 15% |
| EBT Margin | 15% |
| Return on Equity | 11.42% |
| Return on Assets | 6.16% |
| Free Cashflow Yield | 1.92% |
| Cash Flow from Financing (TTM) |
| 10.29 kCr |
| Cash & Equivalents | 327.77 Cr |
| Free Cash Flow (TTM) | 1.95 kCr |
| Free Cash Flow/Share (TTM) | 47.31 |
Balance Sheet | |
|---|---|
| Total Assets | 28.81 kCr |
| Total Liabilities | 13.28 kCr |
| Shareholder Equity | 15.53 kCr |
| Current Assets | 8.29 kCr |
| Current Liabilities | 7.1 kCr |
| Net PPE | 2.93 kCr |
| Inventory | 1.97 kCr |
| Goodwill | 6.49 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.29 |
| Debt/Equity | 0.54 |
| Interest Coverage | 1.86 |
| Interest/Cashflow Ops | 5.1 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1 |
| Dividend Yield | 0.05% |
| Shares Dilution (1Y) | 3% |
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 13% is a good sign.
Growth: Good revenue growth. With NA% growth over past three years, the company is going strong.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Momentum: Stock is suffering a negative price momentum. Stock is down -3.7% in last 30 days.
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 13% is a good sign.
Growth: Good revenue growth. With NA% growth over past three years, the company is going strong.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Momentum: Stock is suffering a negative price momentum. Stock is down -3.7% in last 30 days.
Investor Care | |
|---|---|
| Dividend Yield | 0.05% |
| Dividend/Share (TTM) | 1 |
| Shares Dilution (1Y) | 3% |
| Earnings/Share (TTM) | 42.59 |
Financial Health | |
|---|---|
| Current Ratio | 1.17 |
| Debt/Equity | 0.54 |
Technical Indicators | |
|---|---|
| RSI (14d) | 44.51 |
| RSI (5d) | 26.52 |
| RSI (21d) | 44.09 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Buy |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Buy |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 4, 2025
The stock has experienced a daily loss of 3.74% and a decline of 6.34% over the past six months.
Mankind Pharma's shares have fluctuated between ₹1910.1 and ₹3050 over the past 52 weeks, indicating volatility.
Compared to competitor Sun Pharmaceutical, Mankind has exhibited weaker gains across multiple time frames.
Summary of Mankind Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the Q2 and H1 FY26 earnings call, management outlined a positive outlook for Mankind Pharma, highlighting significant revenue growth amidst operational challenges. For Q2 FY26, the company reported a revenue increase of 21% year-on-year to INR 3,697 crores and a year-to-date (H1 FY26) revenue growth of 23% to INR 7,268 crores. Despite facing supply chain disruptions related to the new GST rollout, the management expects a recovery and aims for growth in the second half of FY26.
Key forward-looking points include:
Chronic Business Growth: The management noted a 200 basis points increase in the chronic share to 37.1% and expects continued double-digit growth in domestic formulations, estimating an outperformance versus the Indian Pharmaceutical Market (IPM) of 1.1x to 1.2x in the latter half of FY26.
Digital Transformation: Partnerships with OpenAI signify investments in digital transformation, facilitating quicker, data-driven decisions intended to enhance profitability and operational efficiency.
Increased R&D Investment: R&D expenses increased to 2.9% of sales, up from 1.9% a year prior, with a commitment to maintain R&D spending within the 2.5%-3% range for the full year.
BSV Integration: Expectations for BSV's growth remain strong, with guidance for a full-year growth of 18%-20%. The second half of the year is projected to demonstrate improved performance as the integration efforts stabilize and ramp up.
Cost Management: The management is focused on optimizing costs and enhancing cash flows, evidenced by a 44% increase in cash flow from operations in H1 FY26 compared to the previous year.
These elements reflect an overarching strategy focused on sustainable and inclusive growth even amid transitional challenges, with a strong emphasis on maintaining competitive advantage in the evolving pharmaceutical landscape.
Understand Mankind Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) | 20.19% |
| Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) | 19.36% |
| Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) | 14.96% |
| SHEETAL ARORA | 4.67% |
| PUJA JUNEJA | 2.79% |
| NPS TRUST A/C - LIC PENSION FUND - UPS - CG SCHEME |
Detailed comparison of Mankind Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 3.92 LCr | 56.98 kCr | -6.90% | -9.20% | 37.48 | 6.88 | - | - |
| DIVISLAB | Divi's Lab | 1.61 LCr |
Comprehensive comparison against sector averages
MANKIND metrics compared to Pharmaceuticals
| Category | MANKIND | Pharmaceuticals |
|---|---|---|
| PE | 50.41 | 33.48 |
| PS | 6.33 | 4.68 |
| Growth | 22.9 % | 7.9 % |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
MANKIND vs Pharmaceuticals (2024 - 2026)
Analysts recommend Mankind Pharma shares as a fundamental 'buy' with a target price of ₹2,750.
Mankind Pharma's stock has shown a positive return of 4.04% over the past year.
Analyst / Investor Meet • 16 Jan 2026 Please find attached intimation regarding Investor Conference Call for Q3 & 9M FY26 with Senior Management |
Credit Rating • 16 Jan 2026 Please find attached Intimation regarding withdrawal and outstanding Credit Ratings granted by ICRA Limited |
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 • 05 Jan 2026 Please find attached Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2025. |
General • 10 Dec 2025 Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) |
General • 10 Dec 2025 Please find attached intimation regard ESG rating |
• 28 Nov 2025 |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Here are the major questions and their detailed answers from the Q&A section of the earnings transcript from November 11, 2025:
Question: "Can you also share exports growth on an organic basis?" Answer: "For the last quarter, we reported mid-single digit growth, and this quarter also continues in the mid-single digits. For modeling purposes, we advise you to take 5%."
Question: "What are the growth prospects for the BSV portfolio?" Answer: "BSV has shown sequential improvement with double-digit growth in domestic specialty and international business. We expect higher growth in H2 and maintain our full year guidance of 18% to 20% growth."
Question: "How do we see growth on the inhaler side over the next 2 to 3 years?" Answer: "We're seeing positive responses for our inhalers, Combihale and Symbicort. Coverage among respiratory specialists has improved, and as seasons change, we expect growth momentum to continue."
Question: "Can we expect outperformance to IPM of double-digit growth as manageable for Mankind in domestic formulation business?" Answer: "We're not satisfied with our current performance. We initially expected quicker results from changes. However, we aim for 1.1x to 1.2x outperformance over IPM in the second half; it may take a couple more quarters to fully realize these expectations."
Question: "How should we think about growth FY '27, FY '28 for BSV?" Answer: "Currently, we expect to maintain double-digit growth. Strategic initiatives in R&D and operations have been implemented, but exact guidance will be provided at the end of Q4."
Question: "Is there a one-off in the higher employee cost this quarter?" Answer: "Yes, the increase is influenced by salary increments starting July and a 3% to 4% increase in headcount from restructuring efforts. The rise in employee costs is a result of these cumulative factors."
Question: "Can you give color on the profitability of the BSV business currently?" Answer: "The BSV business margin is currently lower than the company average but we expect it to reach 26% to 28% in the second half due to higher sales in that period."
Question: "What was the impact of GST higher on OTC versus Rx portfolio?" Answer: "OTC relies more on consumer push than prescriptions, so when GST came into effect, sales dipped more significantly. Additionally, the uneven monsoons impacted our distribution capacity, hindering sales."
Question: "Why are new launches trailing competition?" Answer: "We've gone through significant structural changes and transformations in our workforce, which affected our momentum. We aim to consolidate our market share from earlier successful launches rather than prioritize new ones right now."
Question: "How do you view the challenges now after recent changes?" Answer: "Major changes take time; integrating new personnel and aligning them with Mankind's culture is crucial. As relationships solidify, we expect improvement in performance to manifest."
| 2.61% |
| POONAM JUNEJA | 2.56% |
| ARJUN JUNEJA | 1.98% |
| RAMESH JUNEJA | 1.66% |
| GOVERNMENT PENSION FUND GLOBAL | 1.65% |
| RAJEEV JUNEJA | 1.57% |
| SBI ARBITRAGE OPPORTUNITIES FUND | 1.5% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA LARGE CAP FUND | 1.29% |
| AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND | 1.17% |
| EKLAVYA JUNEJA | 0.94% |
| CHANAKYA JUNEJA | 0.94% |
| MISHKA ARORA | 0.72% |
| RIA CHOPRA JUNEJA | 0.31% |
| AYUSHI JUNEJA SIKRI | 0% |
| PUSHPA RANI AGGARWAL | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.46 kCr |
| -6.30% |
| +4.40% |
| 64.87 |
| 15.41 |
| - |
| - |
| TORNTPHARM | Torrent Pharmaceuticals | 1.36 LCr | 12.2 kCr | +5.20% | +27.00% | 63.59 | 11.15 | - | - |
| CIPLA | Cipla | 1.11 LCr | 29.39 kCr | -8.40% | - | 20.39 | 3.78 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.02 LCr | 36.09 kCr | -5.10% | -6.10% | 18.21 | 2.82 | - | - |
| ALKEM | Alkem Lab | 68.85 kCr | 14.37 kCr | +2.90% | +11.80% | 29.16 | 4.79 | - | - |
| AUROPHARMA | Aurobindo Pharma | 66.52 kCr | 33.03 kCr | -6.00% | -3.90% | 19.43 | 2.01 | - | - |
| 1.7% |
| 3,167 |
| 3,113 |
| 2,813 |
| 2,339 |
| 2,330 |
| 1,964 |
| Profit Before exceptional items and Tax | 15.9% | 622 | 537 | 494 | 847 | 664 | 569 |
| Total profit before tax | 15.9% | 622 | 537 | 494 | 847 | 664 | 569 |
| Current tax | 12.7% | 125 | 111 | 158 | 168 | 139 | 115 |
| Deferred tax | -39.1% | -21.35 | -15.07 | -44.95 | 22 | -14.15 | -19.54 |
| Total tax | 8.4% | 104 | 96 | 113 | 190 | 125 | 95 |
| Total profit (loss) for period | 16.9% | 520 | 445 | 385 | 659 | 543 | 477 |
| Other comp. income net of taxes | 1350% | 23 | -0.76 | 11 | -2.2 | -3.1 | -8.36 |
| Total Comprehensive Income | 22.3% | 543 | 444 | 395 | 657 | 540 | 468 |
| Earnings Per Share, Basic | 18.4% | 12.39 | 10.62 | 9.45 | 16.31 | 13.39 | 11.76 |
| Earnings Per Share, Diluted | 18.5% | 12.38 | 10.6 | 9.44 | 16.28 | 13.37 | 11.74 |
| 378 |
| 318 |
| 270 |
| Other expenses | 7.7% | 2,207 | 2,049 | 1,884 |
| Total Expenses | 5.7% | 7,685 | 7,272 | 6,727 |
| Profit Before exceptional items and Tax | 2% | 2,306 | 2,260 | 1,563 |
| Total profit before tax | 2% | 2,306 | 2,260 | 1,563 |
| Current tax | 12.7% | 470 | 417 | 292 |
| Deferred tax | -358.9% | -48.19 | 20 | 23 |
| Total tax | -3.2% | 422 | 436 | 315 |
| Total profit (loss) for period | 6.7% | 1,945 | 1,823 | 1,248 |
| Other comp. income net of taxes | 151.7% | 4.98 | -6.7 | -4.86 |
| Total Comprehensive Income | 7.3% | 1,950 | 1,817 | 1,243 |
| Earnings Per Share, Basic | 110.7% | 94.8 | 45.52 | 31.16 |
| Earnings Per Share, Diluted | 110.6% | 94.63 | 45.45 | 31.16 |
| Debt service coverage ratio | - | 055 | - | - |
| Interest service coverage ratio | - | 0.0588 | - | - |
| -0.3% |
| 1,935 |
| 1,941 |
| 1,802 |
| 1,811 |
| 1,827 |
| 1,436 |
| Capital work-in-progress | 30% | 248 | 191 | 121 | 113 | 92 | 438 |
| Investment property | - | 0 | 0 | 5.24 | 5.27 | 5.3 | 5.32 |
| Goodwill | 0% | 9.96 | 9.96 | 6.56 | 6.56 | 6.56 | 6.56 |
| Non-current investments | 1.2% | 15,308 | 15,125 | 2,294 | 2,191 | 2,160 | 2,041 |
| Loans, non-current | -51.1% | 5.14 | 9.46 | 36 | 8.74 | 0 | 0 |
| Total non-current financial assets | 0.3% | 15,324 | 15,280 | 2,345 | 2,216 | 2,217 | 2,075 |
| Total non-current assets | 1% | 19,214 | 19,032 | 5,991 | 5,859 | 5,877 | 5,759 |
| Total assets | 4.3% | 24,862 | 23,828 | 13,260 | 11,418 | 10,564 | 9,371 |
| Borrowings, non-current | -24.5% | 3,734 | 4,946 | 4.47 | 5.95 | 7.31 | 3.23 |
| Total non-current financial liabilities | -24.5% | 3,734 | 4,946 | 4.47 | 5.95 | 7.31 | 3.23 |
| Provisions, non-current | 2.4% | 129 | 126 | 119 | 112 | 104 | 89 |
| Total non-current liabilities | -24.1% | 3,869 | 5,097 | 227 | 201 | 279 | 168 |
| Borrowings, current | 52.3% | 3,514 | 2,308 | 203 | 2.62 | 2.43 | 1.46 |
| Total current financial liabilities | 41.6% | 4,804 | 3,394 | 1,528 | 1,035 | 1,059 | 983 |
| Provisions, current | 5.8% | 584 | 552 | 388 | 373 | 332 | 295 |
| Current tax liabilities | - | 12 | 0 | 88 | 42 | 86 | 43 |
| Total current liabilities | 34% | 5,482 | 4,092 | 2,100 | 1,593 | 1,614 | 1,419 |
| Total liabilities | 1.8% | 9,351 | 9,188 | 2,473 | 1,794 | 1,893 | 1,587 |
| Equity share capital | 0% | 41 | 41 | 40 | 40 | 40 | 40 |
| Total equity | 5.9% | 15,511 | 14,640 | 10,787 | 9,624 | 8,671 | 7,784 |
| Total equity and liabilities | 4.3% | 24,862 | 23,828 | 13,260 | 11,418 | 10,564 | 9,371 |
| - |
| Purchase of other long-term assets | - |
| Cash receipts from repayment of advances and loans made to other parties | -88.9% |
| Interest received | 130.4% |
| Other inflows (outflows) of cash | 146.3% |
| Net Cashflows From Investing Activities | -531% |
| Proceeds from issuing shares | - |
| Proceeds from borrowings | 49220.8% |
| Repayments of borrowings | 19083.3% |
| Payments of lease liabilities | 689.5% |
| Interest paid | 6677.3% |
| Other inflows (outflows) of cash | - |
| Net Cashflows from Financing Activities | 101154% |
| Effect of exchange rate on cash eq. | -198.2% |
| Net change in cash and cash eq. | -122.8% |
Allotment of Equity Shares • 26 Nov 2025 Please find attached intimation regarding allotment of 46,582 equity shares pursuant to Mankind Employee Stock Option Plan 2022 |